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Abstract
Introduction: During the course of leprosy, 10 to 50% of indivi-
duals can be surprised by reaction states, which are immune system 
reactions of the patient to Mycobacterium leprae. Leprosy reactions 
constitute the main cause of nerve damage and disability caused by 
leprosy. 
Objective: To analyze the clinical and therapeutic profile of patients 
with leprosy reactions registered in a Dermatology Service in the city 
of Belém-PA. 
Methods: This is a cross-seccional, descriptive study. It was inves-
tigated through analysis of medical records, 52 patients who fit the 
established inclusion criteria. Data were collected in July and August 
2016. 
Results: It was found a predominance of men, from the metropolitan 
region. The clinical form most common of Leprosy was Borderline, 
and the leprosy reaction type 1. The most of reactions occurred right 
after the introduction of multidrug therapy,and more than a half of 
patients with type 1 reaction showed edema of limbs. Regarding the 
type 2, fever and general symptoms were the most common, present 
in all cases. The frequency of neural damage was evident, showing 
reduction of motor force level andloss of protective sensation. 
Conclusion: Early diagnosis and appropriate therapeutic manage-
ment of reactive events is critical to the prevention of disabilities.
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Introduction
Leprosy is a chronic disease caused by Mycobacte-
rium leprae and has a clinical course dependent on 
the interaction between the host immune response 
and that pathogen, which predominantly infects cu-
taneous and peripheral nerve cells, causing injuries 
[1].
During the course of the disease, 10 to 50% of 
leprosy individuals may be surprised by reactional 
conditions or states [2], which are the main cause 
of disability caused by leprosy [3]. In addition, they 
are also important risk factors for retreatment of 
leprosy, and have a great responsibility on treatment 
abandoning [2].
Reaction states or leprosy reactions are reactions 
of the patient's immune system to Mycobacterium 
leprae [4]. They are alterations of the immune sys-
tem, externalized as acute and subacute manifesta-
tions [5], localized or systemic, occurring commonly 
before, during or after the specific treatment of the 
disease. They bear relation to the bacillary quantity 
and the immune response of the host [6].
There are two types of leprosy reactions: reverse 
(RR) or type 1, which is an exacerbated response 
of the cell type immune system, characteristic of 
patients with tuberculoid and dimorphic forms; and 
the type 2 or erythema nodosum reaction (ENH), 
which translates into a hypersensitivity of humoral 
type immunity, and affects carriers of virchowian 
and dimorphic-virchowian forms [7].
Type 1 reactions present the following clinical 
features: infiltration of old lesions associated with 
the appearance of new lesions in the form of sta-
ins, or infiltrated plaques accompanied by edema 
and pain, erythema, vesicle-bullous lesions, ulcera-
tions, hyperesthesia, paresthesia, malaise, pain or 
thickening of peripheral nerves with loss of sen-
sory-motor function and, more rarely, deficiency of 
neural function in absence of symptoms (silent neu-
ropathy), mainly affecting the ulnar and posterior 
tibial nerves, and hands and feet edema [2].
Type 2 or Erythema Nodosum reactions are cha-
racterized by red and painful nodules, which may 
progress to necrosis in the more severe forms [2]. 
They may also be accompanied by symptoms rela-
ted to ocular, hepatic and splenic involvement of 
lymph nodes, peritoneum, testes, joints, tendons, 
muscles, bones and kidneys. In addition, they may 
cause fever and/or alteration of the general state, 
leukocytosis and, usually present in multiple episo-
des [4].
Reactional states are the leading cause of nerve 
damage and disability caused by leprosy. Therefore, 
it is important to perform an early diagnosis, in or-
der to prevent incapacities [3]. Motor disturbances 
are visualized through paresis and paralysis, along 
with atrophies, retractions and joint fixations. Vas-
cular and sweat changes are found when there are 
autonomic disorders [8].
The diagnosis of the reactional states is clinical 
and the treatment adopted varies according to the 
type of reaction [9]. In type 1 reactions, the choice 
drug is prednisone at 1-1.5 mg/kg/day, with gradual 
withdrawal after the disappearance of inflamma-
tory signs. In cases of type 2 reactions, the drug of 
choice is Thalidomide, except in fertile women, at 
a dose of 100-400 mg/day [10].
Although the implications of leprosy reactions on 
the generation of disabilities and the consequences 
for quality of life are recognized, since they produce 
pain, deformities and abstention to work, national 
studies about this problem are still scarce [11].
In this context, the following questions emerged: 
What are the most observed lesions so that the 
diagnosis of leprosy reactions can be established 
early? What is the frequency of patients with neu-
ral damage due to leprosy reactions? What is the 
profile of the patients registered in this Dermatology 
Center?
To answer the questions, this work aims to analy-
ze the clinical and therapeutic profile of patients re-
gistered at a referral center in dermatology of Brazil.
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Methods
This is a descriptive study, performed in a Derma-
tology Service in the city of Belém, Pará, in Brazil. 
Thus, the following criteria were used in the sam-
ple selection: patients belonging to any age group 
and gender who were part of the spontaneous 
demand attended at the Dermatology Service of 
the Universidade do Estado do Pará, from January 
2010 to December 2015, and who had leprosy re-
actions.
The study population was 52 patients with 
Hansen's disease affected by leprosy reactions, 
among a total of 144 leprosy patients.
This study was approved by the Ethics Commit-
tee in Research of Universidade do Estado do Pará, 
CAAE Nº 57167316.2.0000.5174 by the provisions 
of resolution nº 466/2012 of the National Health 
Council and the rules governing research involving 
human beings.
The research started from the authorization of 
the director and the professionals responsible for 
the Dermatology Service. Data collection was con-
ducted in July and August 2016 in the dependences 
of the Dermatology Service. A structured protocol 
with objective questions about the clinical and the-
rapeutic profile of patients with leprosy reactions 
was used to collect the data. The protocol was di-
vided into two phases: the first phase with ques-
tions to identify the socio-demographic profile and 
the second phase with specific questions about the 
topic.
The last phase was to organize the findings into 
a database through Microsoft Excel 2010 software, 
building graphs, charts, and tables. Descriptive sta-
tistics was used for data analysis.
Results
A total of 144 patients with leprosy diagnosis were 
found, and among these, 52 cases presented le-
prosy reactions, corresponding to a prevalence of 
36.11%.
Regarding the socio-demographic aspects, 
38.46% of the total sample was female, and 61.54% 
was male. In terms of age, a similar distribution was 
observed, with 15-29, 30-44 and > 60, correspon-
ding to 25% each. All these data are presented in 
Table 1 below:
There was a predominance of reactional states 
in patients with type 1 reactions. The majority of 
leprosy reactions of this type were present in the 
dimorphic clinical form, followed by tuberculoid and 
virchowian. Only five patients with the type 2 reac-
tion were identified, and 60% of the patients pre-
sented the virchowian clinical form, while the rest 
(40%) had a dimorphic form, as shown in Table 2.
Table 1.  Socio-demographic aspects of patients with 
leprosy reaction. Belém, PA, 2010-2015.
Variables N %
Gender
Male 32 61.54
Female 20 38.46
Age
0 to 14 years old 6 11.54
15 to 29years old 13 25.00
30 to 44years old 13 25.00
45 to 59years old 7 13.46
>60years old 13 25.00
Origin
Metropolitan area 36 69.23
Countryside 16 30.77
Profession
Student 12 23.08
Retired 9 17.31
Housewife/housekeeper 9 17.31
Farmer 3 5.77
Clerk / secretary 3 5.77
Mason 3 5.77
General Services 3 5.77
Others 8 15.38
Not informed 2 3.84
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As for the onset of leprosy reactions in relation to 
the beginning of leprosy treatment, it was observed 
that most of them appeared after the introduction 
of multidrug therapy, as showed in Table 3.
Regarding the clinical manifestations, it was iden-
tified that 51.16% of patients with leprosy type 1 
had edema and/or pain. Old and recent infiltrated 
plaques were other clinical findings very common 
in this reaction. There was also the presence of pa-
resthesia in 39.53% of the patients. The present re-
search showed that fever and general malaise were 
present in 100% of patients with type 2 and mixed 
leprosy reactions. There were also the presence of 
recent infiltrated plaques (40%) and old infiltrated 
plaques (20%), as shown in Figure 1.
The most commonly used drug to treat leprosy 
reactions was prednisone. For type 1 reaction, 
prednisone was used in all cases. For the type 2 
reaction, thalidomide alone was used in 40% of 
the cases and in the remaining 60%, prednisone 
was associated with thalidomide. For type 1 and 2 
reactions, the association between prednisone and 
thalidomide was used in 100% of cases, as presen-
ted in Table 4.
Discussion
The difference between men and women has been 
shown to be similar to other studies, which also 
Table 2.  Distribution of clinical forms of leprosy in 
relation to leprosy, Belém, PA, 2010-2015.
Clinical forms
Type of reaction
Type 1 Type 2 Types 1 & 2
n % n % n %
Undetermined - - - - - -
Tuberculoid 7 16.28 - - - -
Dimorph 31 72.09 2 40 1 25
Virchowian 5 11.63 3 60 3 75
Total 43 100 5 100 4 100
Table 3.  Distribution of leprosy reactions among 
the types of reactions in relation to specific 
treatment leprosy, Belém, PA, 2010-2015.
Period
Reaction
Type 1 Type 2 Types 1 & 2
n % n % n %
Before 16 37.20 2 40 3 37.50
During 17 39.55 - - 4 50
After 10 23.25 3 60 1 12.50
Total 43 100 5 100 8 100
Table 4.  Distribution Therapy used for leprosy reac-
tions in patients with leprosy, Belém, PA, 
2010-2015.
Medications
Reaction
Type 1 Type 2 Types 1 & 2
n % n % n %
Prednisone 
1mg/kg 43 100 - - - -
Thalidomide 
100-400mg
- - 2 40 - -
Prednisone 
+ Thalidomide
- - 3 60 4 100
Total 43 100 5 100 4 100
Figure 1:  Main clinical manifestations resulting 
from leprosy reactions in patients with 
leprosy, Belém, PA, 2010-2015.
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point to this higher prevalence in men [11, 12, 13]. 
The predominance of reactional states among 
men may be associated with a greater delay in 
the search for health services, which hampers the 
development of preventive and early diagnosis ac-
tions [14].
The largest number of patients (69.23%) came 
from the metropolitan area of Belém, in the north 
of Brazil, where the Dermatology Service of the 
University is located. This situation is similar to 
the one in the study of Soares [15] and Pires [16], 
which evidenced a higher demand also coming 
from the metropolitan region, where the research 
was carried out, possibly due to greater ease of 
access.
The clinical forms in which the reactional states 
occurred most frequently were dimorphic (65.38%) 
and virchowian (21.16%). There was a divergence 
from the study by Queiroz [14], who presented a 
higher frequency in the virchowian and dimorphic 
forms. The predominance was the virchowian form, 
with 55.74% of the cases, followed by the dimor-
phous, with 32.79%.
The predominance of reactional states in the pa-
tients studied was type 1, corresponding to 82.69% 
of the cases. This fact was similar to the study done 
by Silva and Griep [11], which demonstrated that 
the majority (58.3%) also presented this type of 
reaction. However, there was a divergence in the 
studies of Gonçalves [17], who presented a higher 
prevalence of type 2 reaction, followed by type 1 
reaction, in his study, which was also performed in 
the southeast region of the country, even though 
the most frequent clinical form in their study was 
dimorphic (81.8%).
The present study found that the vast majority 
(72.09%) of leprosy type 1 reactions were present 
in the dimorphic clinical form. Only five patients 
with the type 2 reaction were identified and 60% 
of them presented the virchowian clinical form. The-
se findings agree with Lima and Aguilar [18], who 
found that most type 1 reactions were present in 
patients with dimorphic leprosy (65.71%) and type 
2 reactions were more evident in patients with vir-
chowian leprosy (87.58%).
As for the onset of leprosy reactions in relation to 
the beginning of leprosy treatment, it was observed 
that 37.5% of the reactions were present before the 
moment of diagnosis, while 62.5% appeared after 
the introduction of the multidrug therapy, 37.5% 
during treatment, and 25% after discharge. This 
fact agrees with the study by Queiroz [14], which 
also showed a lower prevalence of cases before the 
onset of MDT (26.23%), and a greater predominan-
ce after, 73.77% of the cases, being 65.57% during 
treatment, followed by those who presented after 
treatment (8.20%).
Isolated prednisone was used only for patients 
with type 1 reaction, corresponding to 100% of 
these; isolated thalidomide was used only for type 
2 reaction (40%). On the other hand, the asso-
ciation of prednisone and thalidomide was pre-
sent both in patients with type 2 reaction (60%) 
and in mixed reaction (100%). This predominance 
was also evident in the work of Teixeira [2], which 
demonstrated that in type 1 reactions prednisone 
was the most used drug, corresponding to 92.7% 
of patients. For type 2 reaction, the association 
of prednisone and thalidomide corresponded to 
58.1% of the cases followed by thalidomide alone 
in 19.4% of the cases.
Regarding the clinical manifestations, it was iden-
tified that a little more than half (51.16%) of pa-
tients with leprosy type 1 had edema and/ or pain. 
Old infiltrated plaques and recent plaques infiltrated 
were other clinical findings more common in this re-
action, present in 25.58% of patients, each. These 
clinical manifestations of the type 1 reaction were 
also the most prevalent in the work of Teixeira [2]; 
however, old infiltrated plaques and recent infiltra-
ted plaques had a higher frequency in the patients 
surveyed in relation to edema or pain.
The present study showed that fever and general 
malaise were present in 100% of the patients with 
InternatIonal archIves of MedIcIne 
sectIon: InfectIous dIseases
ISSN: 1755-7682
2017
Vol. 10 No. 264
doi: 10.3823/2534
This article is available at: www.intarchmed.com and www.medbrary.com 6
leprosy type 2 reaction. In contrast, none of the 
patients with type 1 reaction had such symptoms. 
There was an agreement with the studies by Foss 
[19] and Putinatti [20], which showed a compromi-
sed general condition with fever and malaise in the 
type 2 reaction, and absence of general compro-
mise in type 1 reaction; this fact can be explained 
because the type 1 reaction is better localized, with 
a sudden increase in cell-mediated immunity; whe-
reas the type 2 reaction presents with involvement 
of humoral and pro-inflammatory mediators, such 
as TNF-alpha and IL-6, presenting importance in the 
immunopathological mechanism and in the symp-
tomatology of ENH [19].
It was evident in the present study that neural 
involvement is frequent in patients with leprosy 
reactions: of the 52 patients studied, 22 (42.31%) 
presented some level of motor force reduction, and 
16 (30.76%) already presented loss of protective 
sensitivity.
Conclusion
The study showed a predominance of males, from 
the metropolitan area of the city of Belém/PA; the-
re was no predominant age group, but the lowest 
number of cases was in the 0 to 14 age range.
According to Madrid classification, the clinical 
form of leprosy most related to the presence of 
leprosy reactions was borderline, and the main type 
of leprosy reaction was type 1.
Regarding the clinical manifestations, the most 
frequent type 1 reaction was the presence of ede-
ma and/ or pain, while in the type 2 reaction state, 
it was the alteration of the general state and fe-
ver, besides the presence of erythematous nodules, 
being an important attention to the quality of life 
of these patients.
It was observed a higher occurrence of leprosy 
reactions right after the institution of the therapy, 
which was recommended by the WHO and the 
Ministry of Health. For type 1 reactions, the use 
of Prednisone was recommended, and for type 2 
reactions, Thalidomide or its association with pred-
nisone.
As study limitation there is incompleteness of in-
formation available in medical records.
Thus, this study contributes to alert about the 
need of early diagnosis and appropriate therapeu-
tic management of reactional events for sequelae 
prevention.
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